This inventor holds 40 USPTO granted patents, primarily in Beta-Carboline Derivatives. Top assignees: Schering Aktiengesellschaft, A/s Ferrosan, Shering Ag. Active years: 1977-2001.
Company Filing History:
39 out of 1,409Â 
2 out of 41Â 
1 out of 7Â Years Active: 1977-2001
Areas of Expertise:
Title: Ralph Schmiechen: A Pioneer in Pharmaceutical Innovations
Introduction: Ralph Schmiechen is a distinguished inventor based in Berlin, Germany, with an impressive portfolio of 40 patents. His work primarily focuses on the development of chemical compounds with potential medicinal applications, showcasing his significant contribution to the field of pharmaceuticals.
Latest Patents: Among his latest innovations are two notable patents concerning quinoxaline derivatives. The first patent involves quinoxaline-carboxylic acid derivatives, presenting a unique formulation of compounds described by specific chemical formulae. The second patent pertains to quinoxaline-phosphonic acid derivatives, detailing the production and medicinal use of these compounds, thereby holding great promise for future therapeutic developments.
Career Highlights: Ralph Schmiechen has made significant strides throughout his career, most notably working with Schering Aktiengesellschaft, a leading international pharmaceutical company. His affiliation with this company allowed him to refine his expertise in pharmaceutical research and development, contributing to several groundbreaking innovations in the industry.
Collaborations: Throughout his career, Schmiechen has collaborated with notable professionals in the field, including Andreas Huth and Dieter Seidelmann. These partnerships have fostered enriching exchanges of ideas and techniques, enhancing the quality and scope of his inventions.
Conclusion: With a solid foundation of patents and a dedication to pharmaceutical innovation, Ralph Schmiechen stands out as a significant contributor to the field. His inventions, particularly in the area of quinoxaline derivatives, not only exemplify his expertise but also highlight the potential for future advancements in medicinal chemistry stemming from his research.